Skip to main content
. 2025 Mar 11;10(5):1460–1467. doi: 10.1016/j.ekir.2025.03.001

Table 3.

Myeloperoxidase staining results in patients with concurrent crescentic glomerulonephritis with membranous nephropathy in comparison to patients with other forms of crescentic glomerulonephritis or membranous nephropathy without crescents

Category Immune deposits by IF ANCA/MPO/PR3 Serology Positive MPO staining cases Capillary loop staining only Mesangial staining only Capillary loop and mesangial staining
Crescentic GN without known infection None + MPO (p-ANCA) 0/10 N/A N/A N/A
None + PR3 (c-ANCA) 0/5 N/A N/A N/A
IgG in membranous pattern + MPO (p-ANCA) 12/14 7/14 0 5/14
IgG in mesangial pattern + MPO (p-ANCA) 4/10 0 4/10 0
IgG in membranous and/or mesangial pattern + PR3 (c-ANCA) 2/10 1/10 0 1/10
Endocarditis-associated crescentic GN None 2/20 MPO+
2/20 PR3+/c-ANCA, 3/20 ANCA positive
0/20 N/A N/A N/A
IgG 1/5 MPO+, 1/5 MPO and PR3+, 1/5 PR3+ 0/5 N/A N/A N/A
Antigen type Serology
Membranous pattern without crescents PLA2R MPO negative 0/5 N/A N/A N/A
EXT2 MPO negative 0/5 N/A N/A N/A
NELL1 MPO negative 0/5 N/A N/A N/A
THSD7A MPO negative 0/5 N/A N/A N/A
Unknown (PLA2R, EXT2, NELL1, and THSD7A negative) MPO Positive 1/4 1/4 0 0

ANCA, antineutrophil cytoplasmic antibodies; EXT, exostosin 1/2; GN, glomerulonephritis; MPO, myeloperoxidase; N/A, not available; NELL1, neural epidermal growth factor-like 1; PLA2R, phospholipase A2 receptor; PR3, proteinase 3; THSD7A, thrombospondin domain containing 7A.